Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

NCT02538705 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Ulcers Related to Diabetic Foot Syndrome

Interventions

DRUG: Neovasculgen

Sponsor

Artgen Biotech

Collaborators

[object Object]
[object Object]